An Aging World Will Fuel ASCENIV Demand And Plasma Treatments
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 4 Analysts
Published
29 Apr 25
Updated
23 Jul 25
AnalystHighTarget's Fair Value
US$35.00
50.9% undervalued intrinsic discount23 Jul
US$17.20
1Y
-2.1%7D
-7.2%